CD274 and neoplasm: Biomarkers such as PD‐L1 expression, tumor mutational burden (TMB), neoantigen load, tumor‐infiltrating lymphocytes, and immune‐regulatory mRNA expression signatures are potentially applicable to the clinical selection of patients for ICIs; however, the detection of these biomarkers relied on the adequate tumor tissue, which is challenging in clinical setting.